Videos
Day 1
Click one or more tumour names to filter results
Vanderbilt University Medical Center
Efficacy of Cabozantinib and Nivolumab in Cluster 1/2 Metastatic Clear Cell Renal Cell Carcinoma: Results from OPTIC RCC, a phase II trial of a novel RNAseq-based biomarker
Netherlands Cancer Institute
Systemic Therapy, Gastrectomy and CRS/HIPEC vs Systemic Therapy Alone for Gastric Cancer with Limited Peritoneal Dissemination: Results of the Randomised PERISCOPE II Trial.
University of Texas MD Anderson Cancer Center
LITESPARK-015: Belzutifan in advanced pheochromocytoma and paraganglioma
Dr. B. R. Ambedkar Institute Rotary Cancer Hospital
Low Dose Pembrolizumab in Addition to Neoadjuvant Anthracycline and Taxane in Triple Negative Breast Cancer: A Randomized Controlled Trial
The Institute of Cancer Research
Randomized Comparison of upfront Magnetic Resonance Imaging Versus Transurethral Resection for Staging New Bladder Cancers: Final survival analysis from the BladderPath trial
University Hospital Essen
Detailed safety analysis of DeLLphi-304: the first phase 3 study to evaluate tarlatamab versus chemotherapy for previously treated small cell lung cancer
Charite-University Medicine Berlin
Durvalumab (D) in combination with bacillus Calmette-Guérin (BCG) for BCG-naïve, high-risk non-muscle-invasive bladder cancer (NMIBC): final analysis of the phase 3, open-label, randomised POTOMAC trial
University of California
Phase 1 study of LY3866288, a potent, highly isoform-selective FGFR3 inhibitor in FGFR3-altered advanced solid tumors (FORAGER-1): Dose optimization
University Medical Center Hamburg - Eppendorf
Pembrolizumab and trastuzumab in combination with FLOT in the perioperative treatment of HER2-positive localized esophagogastric adenocarcinoma – Interim Analysis of the phase II PHERFLOT/IKF-053 trial of the AIO study group (AIO STO 0321)
Fred Hutchinson Cancer Center
Gedatolisib (geda) + fulvestrant ± palbociclib (palbo) vs fulvestrant in patients (pts) with HR+/HER2-/PIK3CA wild-type (WT) advanced breast cancer (ABC): First results from VIKTORIA-1
UNSW Sydney
Regorafenib plus nivolumab vs investigator’s choice of chemotherapy in previously treated gastric or gastroesophageal cancer: INTEGRATE IIb, a randomized phase 3 AGITG Intergroup [NHMRC-CTC/IKF/AIO, ACCRU, TCOG/NHRI] study
